Publications by authors named "John Goudreau"

Claim this Profile
rs10501087, rs1491850 and rs11030094 polymorphisms associated with delayed progression in early-stage Parkinson's disease.
D Luke Fischer, Peggy Auinger, John L Goudreau, Katrina L Paumier, Allyson Cole-Strauss

Front Neurol· November 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effect of Urate-Elevating Inosine on Early Parkinson Disease Progression: The SURE-PD3 Randomized Clinical Trial.

JAMA· September 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Heterozygous VPS13A and PARK2 Mutations in a Patient with Parkinsonism and Seizures.
Steven D Mitchell, Roger L Albin, William T Dauer, John L Goudreau, Christos Sidiropoulos

Case Rep Neurol· June 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
BDNF rs6265 Variant Alters Outcomes with Levodopa in Early-Stage Parkinson's Disease.
D Luke Fischer, Peggy Auinger, John L Goudreau, Allyson Cole-Strauss, Karl Kieburtz

Neurotherapeutics· October 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Restoring pars intermedia dopamine concentrations and tyrosine hydroxylase expression levels with pergolide: evidence from horses with pituitary pars intermedia dysfunction.
Jessica S Fortin, Matthew J Benskey, Keith J Lookingland, Jon S Patterson, Erin B Howey, John L Goudreau

BMC Vet Res· September 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Sex differences by design and outcome in the Safety of Urate Elevation in PD (SURE-PD) trial.
Michael A Schwarzschild, Eric A Macklin, Rachit Bakshi, Shamik Battacharyya, Robert Logan, John L Goudreau

Neurology· October 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Bdnf variant is associated with milder motor symptom severity in early-stage Parkinson's disease.
D Luke Fischer, Peggy Auinger, John L Goudreau, Katrina L Paumier, Allyson Cole-Strauss

Parkinsonism Relat Disord· August 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Critical appraisal of the recent US FDA approval for earlier DBS intervention.
Laura Y Cabrera, John Goudreau, Christos Sidiropoulos

Neurology· July 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Metabolism of Dopamine in Nucleus Accumbens Astrocytes Is Preserved in Aged Mice Exposed to MPTP.
Brittany M Winner, Harue Zhang, McKenzie M Farthing, Lalitha M Karchalla, Keith J Lookingland, John L Goudreau

Front Aging Neurosci· December 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Longer Duration of MAO-B Inhibitor Exposure is Associated with Less Clinical Decline in Parkinson's Disease: An Analysis of NET-PD LS1.
Robert A Hauser, Ruosha Li, Adriana Pérez, Xuehan Ren, Dan Weintraub, John L Goudreau

J Parkinsons Dis· November 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Autonomic and electrocardiographic findings in Parkinson's disease.
Christopher H Gibbons, David K Simon, Meilin Huang, Barbara Tilley, Michael J Aminoff, John Goudreau

Auton Neurosci· July 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Reduced Noradrenergic Signaling in the Spleen Capsule in the Absence of CB and CB Cannabinoid Receptors.
Tyrell J Simkins, David Fried, Kevin Parikh, James J Galligan, John L Goudreau

J Neuroimmune Pharmacol· December 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
FosB and ΔFosB expression in brain regions containing differentially susceptible dopamine neurons following acute neurotoxicant exposure.
Joseph R Patterson, Elizabeth J Kim, John L Goudreau, Keith J Lookingland

Brain Res· October 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Choice of dopaminergic therapy among early, mild Parkinson disease subjects in North America.
John L Goudreau, Adriana Pérez, Michael J Aminoff, James T Boyd, Keith D Burau

J Neurol Sci· July 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comparison of the structure, function and autophagic maintenance of mitochondria in nigrostriatal and tuberoinfundibular dopamine neurons.
Hae-Young Hawong, Joseph R Patterson, Brittany M Winner, John L Goudreau, Keith J Lookingland

Brain Res· October 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Methylmercury impairs canonical dopamine metabolism in rat undifferentiated pheochromocytoma (PC12) cells by indirect inhibition of aldehyde dehydrogenase.
Chelsea T Tiernan, Ethan A Edwin, Hae-Young Hawong, Mónica Ríos-Cabanillas, John L Goudreau

Toxicol Sci· April 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Parkinson's disease severity and use of dopaminergic medications.
John Y Fang, Adriana Pérez, Chadwick W Christine, Maureen Leehey, Michael J Aminoff, John L Goudreau

Parkinsonism Relat Disord· March 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The role of parkin in the differential susceptibility of tuberoinfundibular and nigrostriatal dopamine neurons to acute toxicant exposure.
Matthew J Benskey, Fredric P Manfredsson, Keith J Lookingland, John L Goudreau

Neurotoxicology· January 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Enhanced humoral immunity in mice lacking CB1 and CB2 receptors (Cnr1-/-/Cnr2-/- mice) is not due to increased splenic noradrenergic neuronal activity.
Tyrell Simkins, Robert B Crawford, John L Goudreau, Keith J Lookingland, Barbara L F Kaplan

J Neuroimmune Pharmacol· September 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Inosine to increase serum and cerebrospinal fluid urate in Parkinson disease: a randomized clinical trial.

JAMA Neurol· February 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Sustained resistance to acute MPTP toxicity by hypothalamic dopamine neurons following chronic neurotoxicant exposure is associated with sustained up-regulation of parkin protein.
Matthew Benskey, Ki Yong Lee, Kevin Parikh, Keith J Lookingland, John L Goudreau

Neurotoxicology· July 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The role of de novo catecholamine synthesis in mediating methylmercury-induced vesicular dopamine release from rat pheochromocytoma (PC12) cells.
Chelsea T Tiernan, Ethan A Edwin, John L Goudreau, William D Atchison, Keith J Lookingland

Toxicol Sci· May 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Mutations in SLC20A2 are a major cause of familial idiopathic basal ganglia calcification.
Sandy Chan Hsu, Renee L Sears, Roberta R Lemos, Beatriz Quintáns, Alden Huang, John L Goudreau

Neurogenetics· February 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A call for transparent reporting to optimize the predictive value of preclinical research.
Story C Landis, Susan G Amara, Khusru Asadullah, Chris P Austin, Robi Blumenstein, John L Goudreau

Nature· October 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comparison of the D2 receptor regulation and neurotoxicant susceptibility of nigrostriatal dopamine neurons in wild-type and CB1/CB2 receptor knockout mice.
Tyrell J Simkins, Kelly L Janis, Alison K McClure, Bahareh Behrouz, Samuel S Pappas, John L Goudreau

J Neuroimmune Pharmacol· September 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis